바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev
e-Submission

Vol.74 No.5
Citation Share

Fatal Interstitial Pneumonitis Rapidly Developed after the First Cycle of CHOP with Etoposide Combination Chemotherapy in a Patient with Lymphoma

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2013, v.74 no.5, pp.235-239

Hyung Chul Park (Chonnam National University)


Sung-Hoon Jung (Chonnam National University)

Song Choi (Chonnam National University Hwasun Hospital)
Seung-Shin Lee (Chonnam National University)
Mi-Young Kim (Chonnam National University)


Hyung, C. P. , Sung-Hoon, J. , Song, C. , Seung-Shin, L. , Mi-Young, K. , & (2013). Fatal Interstitial Pneumonitis Rapidly Developed after the First Cycle of CHOP with Etoposide Combination Chemotherapy in a Patient with Lymphoma. Tuberculosis & Respiratory Diseases, 74(5), 235-239.
  • Downloaded
  • Viewed
PDF Download

Abstract

Several chemotherapeutic agents are known to develop pulmonary toxicities in cancer patients, although the frequency of incidence varies. Cyclophosphamide is a commonly encountered agent that is toxic to the lung. Additionally, granulocyte colony-stimulating factor (G-CSF) being used for the recovery from neutropenia can exacerbate lung injury. However, most of the patients reported previously that the drug-induced interstitial pneumonitis were developed after three to four cycles of chemotherapy. Hereby, we report a case of peripheral T cell lymphoma which rapidly developed a fatal interstitial pneumonitis after the first cycle of combined chemotherapy with cyclophosphamide, adriamycin, vincristine, prednisolone, and etoposide and the patient had also treated with G-CSF during neutropenic period.

keywords
Lymphoma, Lung Diseases, Interstitial, Granulocyte Colony-Stimulating Factor, Drug Therapy

Reference

1.

Nakase K, Tsuji K, Nagaya S, Tamaki S, Tanigawa M, Ikeda T, et al. Acute interstitial pneumonitis during chemotherapy for haematological malignancy. Eur J Cancer Care (Engl) 2005;14:336-41.

2.

Meadors M, Floyd J, Perry MC. Pulmonary toxicity of chemotherapy. Semin Oncol 2006;33:98-105.

3.

Azoulay E, Attalah H, Yang K, Herigault S, Jouault H, Brun-Buisson C, et al. Exacerbation with granulocyte colony-stimulating factor of prior acute lung injury during neutropenia recovery in rats. Crit Care Med 2003; 31:157-65.

4.

Aggarwal A, Baker CS, Evans TW, Haslam PL. G-CSF and IL-8 but not GM-CSF correlate with severity of pulmonary neutrophilia in acute respiratory distress syndrome. Eur Respir J 2000;15:895-901.

5.

Wiedermann FJ, Mayr AJ, Hobisch-Hagen P, Fuchs D, Schobersberger W. Association of endogenous G-CSF with anti-inflammatory mediators in patients with acute respiratory distress syndrome. J Interferon Cytokine Res 2003;23:729-36.

6.

Cooper JA Jr, White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis 1986;133:321-40.

7.

Burger RM, Peisach J, Horwitz SB. Activated bleomycin: a transient complex of drug, iron, and oxygen that degrades DNA. J Biol Chem 1981;256: 11636-44.

8.

Lindemann A, Herrmann F, Oster W, Haffner G, Meyenburg W, Souza LM, et al. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood 1989;74: 2644-51.

9.

Yuan L, Inoue S, Saito Y, Nakajima O. An evaluation of the effects of cytokines on intracellular oxidative production in normal neutrophils by flow cytometry. Exp Cell Res 1993;209:375-81.

10.

Iijima S, Tsuji T, Sugita M, Yamada N, Satoh T, Kubo T. Leukocyte activity and occurrence of tissue injury by G-CSF. Nihon Sanka Fujinka Gakkai Zasshi 1993;45: 213-9.

11.

Mendoza JF, Caceres JR, Santiago E, Mora LM, Sanchez L, Corona TM, et al. Evidence that G-CSF is a fibroblast growth factor that induces granulocytes to increase phagocytosis and to present a mature morphology, and that macrophages secrete 45-kd molecules with these activities as well as with G-CSF-like activity. Exp Hematol 1990;18:903-10.

12.

Brieva J. Cyclophosphamide-induced acute respiratory distress syndrome. Respirology 2007;12:769-73.

13.

Katsuya H, Suzumiya J, Sasaki H, Ishitsuka K, Shibata T, Takamatsu Y, et al. Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leuk Lymphoma 2009;50:1818-23.

14.

Ennishi D, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Takeuchi K, et al. Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int J Hematol 2008;87:393-7.

15.

Togashi Y, Masago K, Handa T, Tanizawa K, Okuda C, Sakamori Y, et al. Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer. Clin Lung Cancer 2012;13: 304-11.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy